Ascletis announces positive interim results from its u.s. phase ib trial with asc30, a potentially first-in-class subcutaneous injection small molecule glp-1r agonist

-ultra-long-acting subcutaneous (sq) injection formulation of small molecule asc30 demonstrated a 36-day half-life in patients with obesity, supporting once monthly or less frequent administration. -as previously disclosed, oral tablet formulation of small molecule asc30 demonstrated potentially best-in-class 6.3% weight loss in patients with obesity after a four-week treatment.
ASC Ratings Summary
ASC Quant Ranking